Ghassan Abou-Alfa, MD, MBA

CIO2022 Highlights

Ghassan Abou-Alfa, MD, MBA Discusses the EMERALD-3 Trial

09/30/2022

Dr Abou-Alfa discusses his CIO2022 abstract, "Transarterial Chemoembolization ± (Tremelimumab and Durvalumab ± Lenvatinib) in Hepatocellular Carcinoma: EMERALD-3."

Dr Abou-Alfa discusses his...

09/30/2022

IO Learning

Cases With Panel Discussion: Management Strategy in HCC - Locoregional vs Systemic Treatment

Angela Lamarca , MD, PhD, MSc;

Lorenza Rimass , MD;

Chris J. Verslype , MD, PhD;

Jordi Rimola , MD, PhD;

Ghassan Abou-Alfa , MD, MBA;

Arndt Vogel , MD;

07/06/2023

Progression-free survival in patients with cholangiocarcinoma with FGFR2 fusions or rearrangements: A FIGHT-202 post-hoc analysis of prior systemic therapy response

Background Most cholangiocarcinoma (CCA) patients are diagnosed with advanced disease and are ineligible for surgery. First-line, standard-of-care therapy for patients with advanced/metas...

G. Vaccaro ;

D. Melisi ;

R. Al-Rajabi ;

A. Paulson ;

M. Borad ;

D. Gallinson ;

D. Oh ;

E. Dotan ;

Daniel Catenacci , MD;

Eric Van Cutsem , MD, PhD;

A. Murphy ;

C. Lihou ;

H. Ren ;

K. Bibeau ;

Ghassan Abou-Alfa , MD, MBA;

L. Feliz ;

V. Sahai ;

Arndt Vogel , MD;

A. Hollebecque ;

06/28/2021

How to Integrate and Sequence New Agents in HCC

Ghassan Abou-Alfa , MD, MBA;

07/01/2021

PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib vs gemcitabine + cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement

Background First-line treatment options are limited for patients with advanced cholangiocarcinoma (CCA). Genetic alterations in the fibroblast growth factor receptor (FG...

Teresa Macarulla , MD, PhD;

Sudipta Roychowdhury , MD;

R. Shroff ;

J. Soto ;

G. Pedrioli ;

L. Fumagalli ;

C. dambkowski ;

M. Javle ;

Ghassan Abou-Alfa , MD, MBA;

D. Oh ;

I. Borbath ;

Lovely Goyal ;